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Using gated SPECT, we evaluated the relationship between
admission troponin I, risk area, and myocardial salvage in pa-
tients with a first myocardial infarction treated with abciximab
and primary percutaneous coronary intervention within 6 h.
Methods: In 43 patients, 99mTc-sestamibi was injected before
primary percutaneous coronary intervention. Gated SPECT was
acquired immediately thereafter and was repeated 7 and 30 d
later. The initial risk area and subsequent infarct size were
expressed as a percentage of the left ventricle; salvage index
was the ratio between salvaged myocardium and initial risk
area; left ventricular ejection fraction was calculated using the
quantitative gated SPECT software. Results: On admission, 20
patients showed elevated troponin I and had a larger risk area
(P  0.03) than did the group with normal troponin I. Infarct size
at 30 d (15% 12% vs. 13% 13%) and salvage index (0.63
0.27 vs. 0.60 0.28) were not significantly different between the
2 groups. Ejection fraction was lower in the group with high
troponin I on admission (36% 10% vs. 41% 11%, P 0.05)
and at 7 d (41%  11% vs. 48  10, P  0.03). At 30 d,
improvement was greater in the group with high troponin I, and
ejection fraction became comparable. Conclusion: Patients
with high troponin I on admission have a larger initial risk area,
but if they undergo primary percutaneous coronary intervention
within 6 h and are treated with abciximab, myocardial salvage
and functional recovery are similar to those observed in patients
with normal troponin I, and no unfavorable relationship between
high troponin I values on admission and myocardial salvage is
registered.
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Elevated plasma levels of cardiac troponin identify pa-
tients with acute coronary syndromes at high risk for sub-
sequent cardiac events (1). Also in acute myocardial infarc-
tion treated by primary percutaneous coronary intervention,
elevated troponin levels on admission are associated with a
worse short- and long-term prognosis (2–4). The relation-
ship between high troponin and negative clinical outcome
remains unclear, but microvascular dysfunction may play a
role (4). In infarct patients, administration of the glyco-
protein IIb/IIIa inhibitor abciximab improves the rate of
successful percutaneous coronary intervention after stent
deployment, microvascular perfusion, left ventricular func-
tional recovery, and clinical outcome (5–7). These benefits
are more evident when abciximab administration is started
before percutaneous coronary intervention (6). Therefore,
one might speculate that abciximab treatment begun before
percutaneous coronary intervention, by limiting microvas-
cular damage, would be particularly helpful in infarct pa-
tients with elevated troponin on admission, according to
what has been reported for patients who have acute coro-
nary syndromes without ST elevation (8,9).
Directly visualizing the area at risk on admission and the
residual perfusion defect early and late after reperfusion,
and then deriving an estimate of the extent of salvaged
myocardium, could be an effective method to verify this
hypothesis. 99mTc-Sestamibi SPECT represents a suitable
tool to assess myocardial salvage in infarct patients un-
dergoing reperfusion therapy (10 –12). Furthermore, the
use of gated SPECT offers the unique opportunity to also
measure ejection fraction (13,14) and, thus, assess func-
tional recovery after primary percutaneous coronary in-
tervention (15). The aim of this study was to use gated
SPECT to examine the changes in both myocardial perfu-
sion and ventricular function in patients treated with abcix-
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imab and primary percutaneous coronary intervention, tak-
ing into account their troponin I level on admission.
MATERIALS AND METHODS
Patient Population
Between September 2001 and June 2003, 129 consecutive pa-
tients with a first acute myocardial infarction were admitted to our
emergency department and scheduled for primary percutaneous
coronary intervention within 6 h of symptom onset. The diagnosis
of acute myocardial infarction was based on typical chest pain
lasting for 30 min and associated with 0.1 mV ST-segment
elevation in at least 2 contiguous electrocardiographic leads. Be-
cause of the limited time that the nuclear medicine laboratory was
available, only 46 patients could be included in the study protocol.
In 3, however, clinical instability precluded transport to the nuclear
medicine laboratory after percutaneous coronary intervention.
Thus, the final study population included 43 patients (35 men, 8
women; mean age; 62  12 y). None had heart disease other than
coronary artery disease, and all were willing to participate in the
study.
Study Protocol
On admission to the emergency department, all patients re-
ceived aspirin (500 mg), heparin (bolus of 60 U/kg of body weight,
to a maximum of 5,000 U, followed by a continuous infusion of 7
U/kg/h), clopidogrel (300 mg), and abciximab (bolus of 0.25
mg/kg of body weight, followed by a continuous infusion of 0.125
g/kg/min, to a maximum of 10 g/min, for 12 h). The patients
were then transferred to the catheterization laboratory, where
99mTc-sestamibi (1,110 MBq) was injected. Immediately after
tracer injection, the patients underwent selective coronary angiog-
raphy and primary percutaneous coronary intervention. Gated
SPECT was performed within 6 h of tracer injection to assess the
extent and severity of the initial perfusion defect and ejection
fraction. Subsequently, patients underwent baseline resting gated
SPECT at 7 and 30 d of index infarction to assess changes in the
extent of myocardial perfusion defect and in ejection fraction. All
patients gave informed consent to participate in the study, which
was approved by the Ethics Committee of our institutions.
Coronary Angiography and Mechanical
Revascularization
Selective coronary angiography followed by primary percuta-
neous coronary intervention was performed using standard mate-
rial. Two experienced angiographers reviewed the angiograms
without knowledge of patient data. Coronary flow in the infarct-
related artery before and after percutaneous coronary intervention
was graded according to the classification of the Thrombolysis in
Myocardial Infarction (TIMI) trial (16). Percutaneous coronary
intervention was considered successful in the presence of TIMI
grade 3 coronary flow in the treated vessel, with a residual steno-
sis  20% (17).
Sample Collection and Analysis
Venous blood for troponin I analysis was collected immediately
after the patient arrived in the emergency department. Cardiac
troponin I was determined using an immunometric method (Di-
mension RxL; Dade Behring). Its lowest measurable troponin I
concentration is 0.04 g/L, and the lowest troponin I concentration
that can be reproducibly measured with an interassay coefficient of
variation 10% is 0.15 g/L (18). This latter value was the cutoff
used to discriminate troponin I status.
Gated SPECT
Images were acquired using a previously described method
(19). Data were processed and perfusion defect extent and ejection
fraction were calculated by an automated and validated method
(13,15). Initial perfusion defect (area at risk) and infarct size at 7
and 30 d were calculated; the difference between infarct size and
area at risk indicated the extent of myocardial salvage. Initial
perfusion defect, infarct size at follow-up, and extent of myocar-
dial salvage were expressed as a percentage of the left ventricle.
The salvage index was calculated as the ratio between myocardial
salvage and area at risk (12).
Statistical Analysis
Results are expressed as mean  SD. Comparisons within
groups were made with the Wilcoxon signed rank test. Compari-
sons between groups were made with the Mann–Whitney U test.
Proportions were compared using the Fisher exact test. Correla-
tions were calculated using the Pearson correlation coefficient. A
P value  0.05 was considered statistically significant.
RESULTS
Baseline Clinical and Angiographic Characteristics
The study population was stratified according to troponin
I level on admission: 20 patients showed elevated values
(mean, 2.39  2.52 g/L; range, 0.16–7.86 g/L), whereas
23 patients had troponin I values within the normal range
(mean, 0.08  0.04 g/L; range, 0.05–0.14 g/L). Table 1
compares the features of these 2 groups. No significant
TABLE 1
Comparison of Clinical and Angiographic Characteristics
Between Patients With and Patients Without Elevated
Troponin I Level on Admission
Characteristic
High
troponin I
Normal
troponin I P
Age (y) 63  13 61  10 NS
Men 16 (80) 19 (83) NS
Hypertension 6 (30) 9 (39) NS
Diabetes mellitus 6 (30) 3 (13) NS
Hypercholesterolemia 9 (45) 12 (52) NS
Current smoker 9 (45) 13 (57) NS
Time (min) from symptom
onset to
Admission 192  118 99  74 0.005
Mechanical reperfusion 271  118 172  82 0.003
Multivessel disease 10 (50) 12 (52) NS
Infarct-related artery
Left anterior descending 12 (60) 7 (30) NS
Left circumflex 2 (10) 3 (13) NS
Right coronary 6 (30) 13 (57) NS
TIMI flow 2–3 before
procedure 6 (30) 9 (39) NS
NS  not statistically significant.
Except where otherwise indicated, data are numbers of patients,
with percentages in parentheses.
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differences were observed between patients with and pa-
tients without high troponin I on admission for most base-
line clinical characteristics. There was a longer delay be-
tween symptom onset and admission and between symptom
onset and reperfusion therapy in the patients with high
troponin I. Similarly, if the 86 patients excluded from the
study because the initial gated SPECT study was not feasi-
ble were stratified according to the admission troponin I
level, the intervals between symptoms, admission, and
reperfusion were the only significantly different parameters
(patients with high troponin I showed longer intervals).
In the patient population, the time from symptom onset to
presentation correlated significantly with the admission tro-
ponin I level (r  0.65; P  0.0001). All patients included
in the study received a coronary stent. Percutaneous coro-
nary intervention was successful in 39 (91%) patients,
whereas recanalization with postintervention TIMI flow 2
was observed in 4 patients, 3 of whom had high troponin I
on admission. Table 2 compares some indicators of reper-
fusion effectiveness in the 2 groups and shows the absence
of significant differences.
Clinical Outcome
Only 1 patient with high troponin I died in the hospital
before the 30-d scintigraphic evaluation. Therefore, the 30-d
data of the group with high troponin I include 19 patients
only. During the 30-d follow-up, no patient experienced
acute coronary syndromes or underwent revascularization
of the target vessel.
Gated SPECT
The scintigraphic findings of the entire population are
reported in Table 3. The initial area at risk was larger (P 
0.03) in the group with high troponin I than in the group
with normal troponin I. However, at 7 d the perfusion
defects already were no longer significantly different, and at
30 d the final infarct size was similar in the 2 groups (Fig.
1). The salvage index at 7 and 30 d was not significantly
different between the 2 groups (Fig. 2).
The admission ejection fraction was significantly lower in
the group with high troponin I (P  0.05). The improve-
ment in ejection fraction at 7 d was significant in both
groups, and at the 7-d evaluation, ejection fraction was still
significantly lower (P  0.03) in the group with high
troponin I. Between 7 and 30 d, however, the improvement
in ejection fraction was larger in the group with high tro-
ponin I, and hence ejection fraction at 30 d was similar in
the 2 groups (Fig. 3).
Taking into account the longer interval between symp-
toms and admission for the group with high troponin I, data
on the patients of the 2 groups admitted within 3 h of
symptom onset were analyzed separately. There were 11
patients with high troponin I and 21 with normal troponin I.
The risk area was larger in the group with high troponin I
(40%  13% vs. 30%  17%), but the difference was not
significant (P  0.09). However, the subsequent evolution
of the perfusion defect led to an equal extent at 30 d, with
the same salvage index (0.66  0.29 vs. 0.61  0.27).
Similarly, the left ventricular ejection fraction, which was
TABLE 2
Comparison of Angiographic, Laboratory, and
Electrocardiographic Indicators of Reperfusion Results
Between Patients With and Patients Without Elevated
Troponin I Level on Admission
Indicator High troponin I
Normal
troponin I P
TIMI flow 0–1 after
procedure 0 0 NS
TIMI flow 2 after
procedure 3 (15) 1 (4) NS
TIMI flow 3 after
procedure 17 (85) 22 (96) NS
Creatine kinase peak (U/L) 3,303  2,209 2,220  2,007 NS
Troponin I peak (g/L) 123  92 87  80 NS
60-min ST-segment
resolution (%) 69  27 70  28 NS
NS  not statistically significant.
Except where otherwise indicated, data are numbers of patients,
with percentages in parentheses.
TABLE 3
Comparison of Perfusion and Functional Data in Study Population Stratified by Troponin I Level on Admission
Data High troponin I Normal troponin I P
Perfusion defect extent on admission 40  12 30  16 0.03
Perfusion defect extent at 7 d 22  14 17  16 NS
Salvage index at 7 d 0.49  0.28 0.50  0.31 NS
Perfusion defect extent at 30 d 15  12 13  13 NS
Salvage index at 30 d 0.63  0.27 0.60  0.28 NS
Ejection fraction on admission 36  10 41  11 0.05
Ejection fraction at 7 d 41  11 48  10 0.03
Ejection fraction at 30 d 50  10 50  10 NS
NS  not statistically significant.
Except for salvage index, all data are percentages.
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slightly lower in the group with high troponin I on admis-
sion (38% 10% vs. 41% 11%), reached the same value
at 30 d (52%  12% vs. 50%  11%).
Because the left anterior descending artery showed a
higher likelihood of being the infarct-related artery in the
group with high troponin I, we also performed a separate
analysis excluding patients with involvement of the left
anterior descending artery. The initial risk area was larger in
the 8 patients with high troponin I than in the 16 with
normal troponin I (32% 11% vs. 22% 9%, P 0.065);
however, the salvage index (0.57  0.30 vs. 0.65  0.28)
and the left ventricular ejection fraction (56%  8% vs.
52%  7%) at 30 d were similar in the 2 groups.
DISCUSSION
Recent studies have shown that among patients with
acute myocardial infarction undergoing primary percutane-
ous coronary intervention, an elevated troponin level on
admission identified a subgroup at higher risk for in-hospital
and long-term cardiac events (2–4). A lower success rate of
primary percutaneous coronary intervention, the presence of
microvascular dysfunction that limits myocardial salvage,
and a higher incidence of malignant reperfusion arrhythmias
have been proposed as possible mechanisms of the worse
outcome in patients with an elevated troponin level on
admission (2,4,20).
In our study, suboptimal epicardial flow (TIMI flow  3)
after percutaneous coronary intervention was more fre-
FIGURE 2. Salvage index in study patients. Patients with
elevated troponin I level on admission are indicated by black
bars; those with normal troponin I level, by white bars.
FIGURE 3. Changes in left ventricular ejection fraction (LVEF)
after primary percutaneous intervention. Patients with elevated
troponin I level on admission are indicated by black bars; those
with normal troponin I level, by white bars.
FIGURE 1. Myocardial perfusion changes in study patients.
Patients with elevated troponin I level on admission are indi-
cated by black bars; those with normal troponin I level, by white
bars. LV  left ventricle.
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quently observed in the group with high troponin I, in
agreement with previous studies that showed elevated tro-
ponin levels on admission to be an independent predictor of
a lower success rate for primary percutaneous coronary
intervention (2,4). In these studies, failure to achieve opti-
mal reperfusion was associated with a worse outcome.
However, this was not the only mechanism to explain the
relationship between high troponin and adverse clinical
outcome, because troponin I elevation remained an inde-
pendent predictor of cardiac events also in patients under-
going successful percutaneous coronary intervention (2).
Microvascular dysfunction that compromised myocardial
perfusion despite normal epicardial flow after percutaneous
coronary intervention might be another involved mecha-
nism. Giannitsis et al. showed that, despite TIMI 3 flow
after revascularization, infarct patients with an elevated
troponin level on admission had more severely impaired
myocardial perfusion as indicated by serum marker release
kinetics and resolution of ST-segment elevation (4). The
microvascular dysfunction that impairs myocardial perfu-
sion, however, could be suspected to limit myocardial sal-
vage as well. Thus, pharmacologic interventions able to
reduce the extent of microvascular damage could be partic-
ularly useful in these patients. In our study, we examined a
patient population who received coronary stents and the
glycoprotein IIb/IIIa antagonist abciximab before percuta-
neous coronary intervention to improve epicardial and mi-
crovascular flow (5–7). Glycoprotein IIb/IIIa inhibitors
have been demonstrated to be more effective in patients
with non-ST elevation acute coronary syndromes and ele-
vated troponin levels than in those with normal troponin
levels (8,9). We did not find a significant difference in
salvage index at 7 and 30 d between the patient groups
stratified according to troponin I level on admission. Be-
cause the group with high troponin I had a larger area at
risk, the extent of myocardial salvage was even greater than
that observed in the group with normal troponin I. Conse-
quently, in our study, an elevated troponin I level was not
associated with impaired tissue reperfusion. These results
support the hypothesis that the use of coronary stenting and
administration of abciximab before percutaneous coronary
intervention prevent the unfavorable relationship between
elevated troponin I on admission and myocardial salvage.
Indeed, the different results observed by Giannitsis et al.
might be explained by their having placed coronary stents in
75% of patients and given abciximab to just a minority
(35%) of patients—those with suboptimal angiographic re-
sults and compromised epicardial flow after percutaneous
coronary intervention (4). Conversely, data in agreement
with ours have recently been reported for patients with
elevated C-reactive protein level on admission (21).
The use of gated SPECT to assess left ventricular func-
tion from perfusion data is a novel contribution of this
study. The evaluation of risk area and final infarct size is
accepted as a reliable surrogate endpoint for studies about
therapeutic options for acute myocardial infarction (22). On
the other hand, the prognostic implications of left ventric-
ular ejection fraction after acute myocardial infarction are
well known (23). Therefore, the advantages offered by
gated SPECT over the traditional nongated technique could
be particularly important for studies comparing different
treatment strategies for acute myocardial infarction, because
in this setting a reproducible assessment of both perfusion
and functional changes is mandatory (10–12,24–26). To
our knowledge, this was the first study to show that the
value of repeated perfusion imaging in acute myocardial
infarction can be increased by adding repeated measure-
ments of left ventricular ejection fraction. However, this
approach has limitations for the evaluation of left ventric-
ular function. Although an inverse relationship between
infarct size and left ventricular ejection fraction has been
demonstrated, no data are available directly comparing the
2 parameters on the basis of a single gated SPECT study.
One must also consider that the first ejection fraction was
measured after revascularization and that, therefore, the
presence of some degree of very early improvement was
possible although quite unlikely because of myocardial
stunning (10).
Other limitations of the present study must be considered.
Because of the small number of patients, confounding ef-
fects from the longer reperfusion delay and higher incidence
of anterior infarctions in the high troponin I group cannot be
excluded with certainty. As for the interval between symp-
tom onset and reperfusion, however, the finding of equally
effective myocardial salvage in the group with high tropo-
nin I is confirmed when the analysis is restricted to patients
admitted within 3 h. The observation that the left anterior
descending artery had a higher likelihood of being the infarct-
related artery in patients with high troponin I is consistent
with previous reports (2,4,27). In our series, however, the
location of the culprit lesion apparently did not influence the
effectiveness of reperfusion, as confirmed by the finding
that patients without involvement of the left anterior de-
scending artery showed a similar salvage index and ejection
fraction at 30 d independently of the presence or absence of
high troponin I at admission. The microvascular dysfunc-
tion in patients with high troponin I was previously dem-
onstrated (4), but because abciximab treatment was not
randomized in our series, we have no data about the poten-
tial consequences of high troponin I levels on subsequent
myocardial salvage in the absence of abciximab adminis-
tration. Because of the small number of patients in the
population and the shortness of the follow-up, we could not
establish whether the absence of differences in myocardial
salvage in patients with and patients without high troponin
I also implies a similar prognosis. However, the direct
demonstration of myocardial salvage is a widely accepted
endpoint for testing the effectiveness of treatment in pa-
tients with acute myocardial infarction (22), and the finding
of preserved left ventricular function reinforces its positive
prognostic implications. Because we selected patients
treated with primary percutaneous coronary intervention
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early (6 h) after symptom onset, the results of our study
might not be valid in patients whose revascularization was
more delayed or who underwent other types of reperfusion
therapy. However, the time independence of treatment ef-
fectiveness in primary percutaneous coronary intervention
has recently been reported (28).
CONCLUSION
An elevated troponin I level on admission identifies a
high-risk subgroup of patients with acute myocardial infarc-
tion. Microvascular dysfunction limiting myocardial sal-
vage has been proposed as one of the possible mechanisms
that link a high troponin I level on admission to a worse
outcome. According to our results, patients with high tro-
ponin I levels on admission have larger initial risk areas
than do other infarct patients. However, for our patients to
whom administration of abciximab started before percuta-
neous coronary intervention, myocardial salvage was
equally effective both in those with and those without
elevated troponin I levels, so that the suspected unfavorable
relationship between elevated troponin I level and myocar-
dial salvage was not registered.
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